

CALL FOR DATA PARTNERS IN MM

OCTOBER 2025



HARMONY
ALLIANCE FOUNDATION

The **HARMONY Alliance Foundation** is launching a **Call for Data Partners** aimed at collecting data to understand treatment effectiveness, showcasing the extent of unmet needs, and generating supporting evidence that the integration of novel treatment strategies after first relapse will improve patient outcomes and drug resistance.

Collecting real-world evidence to assess treatment paradigm and management of early-relapse multiple myeloma

Multiple myeloma (MM) treatment is evolving with the introduction of novel therapies and their earlier integration into standard care. In the initial treatment phase, novel combinations, particularly quadruplet regimens including proteasome inhibitors, immunomodulatory drugs, and anti-CD38 monoclonal antibodies, have become standard for both transplant-ineligible and transplant-eligible patients, leading to significant improvements in progression-free survival (PFS) and overall survival (OS). Many of these treatments require ongoing use, and patients often become refractory at the time of relapse or when the disease progresses.

Current guidelines indicate that two major patient groups predominate at first relapse, requiring the initiation of a second-line therapy: those refractory to lenalidomide and those refractory to both lenalidomide and anti-CD38 monoclonal antibodies. This situation limits treatment options, notably for patients who relapse early, which is within 12 to 18 months of starting therapy. These patients are considered high-risk, and as such, there is a critical need to collect real world evidence to support research and generate better treatment options as soon as possible.

Benefits for Data Partners

- * **Access** to the resulting database.
- * Possibility to **submit research questions** to the HARMONY Platform.
- * Access to **dashboards** to facilitate data visualization.
- * **Authorship rights** in any publication resulting from the use of your data.
- * **Networking** opportunities.
- * Potential **funding** opportunities.

Would you like to join?

[Fill out the Form and send your Expression of Interest](#)



Deadline for applications

30 October 2025, at 17:00 CET

María Victoria Mateos

Member of the HARMONY Alliance Board of Trustees

'The management of early-relapse multiple myeloma is becoming increasingly complex, as many patients are already refractory to lenalidomide and/or anti-CD38 monoclonal antibodies after only one prior line of therapy. Current real-world data are limited, mostly derived from U.S. databases or clinical trial populations, and highlight the urgent need for global insights into treatment practices. Novel immunotherapeutic strategies—particularly T-cell-redirecting therapies such as CAR-T cells and bispecific antibodies—offer the promise of transforming outcomes in this setting. Their integration into earlier lines of therapy, supported by both clinical trial evidence and real-world validation, will be essential to overcome the unmet needs of this difficult-to-treat population and to prevent the poor outcomes associated with triple-class exposure.'

